Current Report Filing (8-k)
May 13 2022 - 04:34PM
Edgar (US Regulatory)
0001292519
false
0001292519
2022-05-11
2022-05-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 11, 2022
Date of Report (Date of earliest event reported)
INVIVO THERAPEUTICS HOLDINGS CORP.
(Exact Name of Registrant as Specified in
Charter)
Nevada |
001-37350 |
36-4528166 |
(State or Other |
(Commission File Number) |
(IRS Employer |
Jurisdiction of Incorporation) |
|
Identification No.) |
One Kendall Square, Suite B14402
Cambridge, Massachusetts 02139
(Address of Principal Executive Offices)
(Zip Code)
(617) 863-5500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, $0.00001 par value per share |
|
NVIV |
|
The Nasdaq Capital Market |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01. Other Events.
As previously disclosed by InVivo Therapeutics Holdings Corp. (the
“Company”) on that certain Current Report on Form 8-K filed on May 21, 2021, with the U.S. Securities and Exchange Commission
(the “SEC”), on May 19, 2021, the Company received a written notice (the “Initial Notice”) from the Listing Qualifications
department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing
Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share of the Company’s common stock (the “Minimum
Bid Price Requirement”). The Initial Notice provided the Company 180 calendar days, or until November 15, 2021, to regain compliance
with the Minimum Bid Price Requirement.
Further, as previously disclosed by the Company on that certain Current
Report on Form 8-K filed on November 16, 2021 with the SEC, on November 16, 2021, the Company received a written notice from the Listing
Qualifications department of Nasdaq that the Company had been granted an additional 180 calendar days, or until May 16, 2022, to regain
compliance with the Minimum Bid Price Requirement.
On May 11, 2022, the Company received a letter (the “Compliance
Letter”) from the Listing Qualifications department of Nasdaq notifying the Company that it has regained compliance with the Minimum
Bid Price Requirement. The Compliance Letter noted that (i) the Company’s common stock had a closing bid price of at least $1.00
for ten consecutive trading days from April 26, 2022, to May 10, 2022, and (ii) the Company has regained compliance with
the Minimum Bid Price Requirement. Accordingly, Nasdaq considers the matter closed.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INVIVO THERAPEUTICS HOLDINGS CORP. |
|
|
|
Date: May 13, 2022 |
By: |
/s/ Richard Toselli, M.D. |
|
Name: |
Richard Toselli, M.D. |
|
Title: |
Chief Executive Officer |
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Feb 2024 to Mar 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2023 to Mar 2024